- Home
- CELZ vs CDT Comparison
CELZ vs CDT Comparison
Compare CELZ & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELZ
- CDT
- Stock Information
- Founded
- CELZ 1998
- CDT 2019
- Country
- CELZ United States
- CDT United States
- Employees
- CELZ N/A
- CDT N/A
- Industry
- CELZ Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- CELZ Health Care
- CDT Health Care
- Exchange
- CELZ Nasdaq
- CDT Nasdaq
- Market Cap
- CELZ 5.5M
- CDT 5.3M
- IPO Year
- CELZ N/A
- CDT N/A
- Fundamental
- Price
- CELZ $2.02
- CDT $0.39
- Analyst Decision
- CELZ
- CDT
- Analyst Count
- CELZ 0
- CDT 0
- Target Price
- CELZ N/A
- CDT N/A
- AVG Volume (30 Days)
- CELZ 34.9K
- CDT 768.1K
- Earning Date
- CELZ 05-09-2025
- CDT 05-15-2025
- Dividend Yield
- CELZ N/A
- CDT N/A
- EPS Growth
- CELZ N/A
- CDT N/A
- EPS
- CELZ N/A
- CDT N/A
- Revenue
- CELZ $14,000.00
- CDT N/A
- Revenue This Year
- CELZ N/A
- CDT N/A
- Revenue Next Year
- CELZ N/A
- CDT N/A
- P/E Ratio
- CELZ N/A
- CDT N/A
- Revenue Growth
- CELZ 55.56
- CDT N/A
- 52 Week Low
- CELZ $1.69
- CDT $0.51
- 52 Week High
- CELZ $6.90
- CDT $350.00
- Technical
- Relative Strength Index (RSI)
- CELZ 44.81
- CDT 31.63
- Support Level
- CELZ $1.94
- CDT $0.38
- Resistance Level
- CELZ $2.20
- CDT $0.41
- Average True Range (ATR)
- CELZ 0.14
- CDT 0.04
- MACD
- CELZ 0.04
- CDT 0.01
- Stochastic Oscillator
- CELZ 40.00
- CDT 9.89
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.